Baypoint Bio Licenses Ovarian, Breast Cancer Dx IP from MD Anderson | GenomeWeb

NEW YORK (GenomeWeb News) – Baypoint Biosystems said today it has licensed predictive biomarker intellectual property from the University of Texas MD Anderson Cancer Center in Houston.

The privately held company has obtained exclusive, worldwide rights to commercialize certain proteomics IP and clinical biomarkers for predicting therapeutic responses for certain ovarian and breast cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.